Therapeutic effects of switching CNI from Tacrolimus to Cyclosporine on renal transplant patients infected with BK polyoma virus

Therapeutic effects of switching CNI from Tacrolimus to Cyclosporine on renal transplant patients infected with BK polyoma virus - Therapeutic effects of switching CNI from Tacrolimus to Cyclosporine on renal transplant patients infected with BK polyoma virus

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005269

Enrollment

Registered

2011-04-01

Start date

2011-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal transplantation

Interventions

Switch Tacrorimus to Cyclosporine and control blood concentration of Cyclosporine below 150ng/mL

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Renal transplant recipients BK polyoma virus over 5000 c/mL Tacrolimus and Mycophenolate mofetil are used as immunosuppressants

Exclusion criteria

Exclusion criteria: Patients with a history of drug sensitivity. Patients with being disqualified by doctors.

Design outcomes

Primary

Measure	Time frame
Alteration in viral load of BK virus(DNA copies/mL)	—

Secondary

Measure	Time frame
1) serum creatinine level 2) acute rejection	—

Countries

Japan

Contacts

Public ContactShiro Takahara

Osaka University Graduate School of Medicine Department of Advanced Technology for Transplantation

kakuta@uro.med.osaka-u.ac.jp06-6879-5111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026